XK
CRSP icon

Xact Kapitalforvaltning’s CRISPR Therapeutics CRSP Stock Holding History

Xact Kapitalforvaltning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,400
Closed -$268K – 1323
2019
Q4 		$268K Buy
+4,400
New +$240K ﹤0.01% 1285
2019
Q3 		– Sell
-4,400
Closed -$207K – 1431
2019
Q2 		$207K Buy
+4,400
New +$176K ﹤0.01% 1376

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Xact Kapitalforvaltning's CRSP Position: Q1 2020 in Review

Xact Kapitalforvaltning sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 4,400 shares — an estimated $268K sold.

Xact Kapitalforvaltning first reported a position in CRSP in Q2 2019 and held it in 2 quarters. The position peaked at $268K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Xact Kapitalforvaltning reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 4,400 CRISPR Therapeutics shares in Q1 2020, an estimated $268K.
  • Xact Kapitalforvaltning first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 2 quarters.
  • Xact Kapitalforvaltning's CRISPR Therapeutics position peaked at $268K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.